Venus Concept (VERO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual and Special Meeting scheduled for June 25, 2025, to be held virtually for broader participation and cost savings.
Six key proposals include director elections, auditor ratification, and approval of share issuances related to preferred stock and convertible notes.
Board recommends voting in favor of all proposals, citing balance sheet improvements and strategic objectives.
Only stockholders as of April 28, 2025, are eligible to vote; quorum requires a majority of voting power present or represented by proxy.
Voting matters and shareholder proposals
Election of three Class II directors to serve until 2028.
Ratification of MNP LLP as independent registered public accounting firm for 2025.
Approval of share issuances upon conversion of Series Y, Series X, and Senior Preferred Stock, and October 2023 Convertible Note, all subject to Nasdaq rules.
Board recommends voting for all proposals; failure to approve certain proposals limits conversion rights under Nasdaq rules.
Stockholder proposals for the 2026 meeting must be submitted by December 31, 2025.
Board of directors and corporate governance
Board consists of seven directors divided into three staggered classes; majority are independent per Nasdaq standards.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all comprised of independent directors.
Board met 15 times in 2024; all directors attended at least 75% of meetings.
Code of Business Conduct and Ethics and formal governance guidelines are in place.
Latest events from Venus Concept
- Revenue down 17% year-over-year, but debt reduced and margin improved amid ongoing risks.VERO
Q2 20241 Feb 2026 - Q3 2024 revenue fell 15% year-over-year as debt was cut by 54% and losses persisted.VERO
Q3 202414 Jan 2026 - Revenue fell 13% in Q4 and 15% for FY24; debt cut by 47% and Q1 2025 revenue to exceed $14M.VERO
Q4 202424 Dec 2025 - Shelf registration enables up to $30.4M in securities sales for global medical technology expansion.VERO
Registration Filing16 Dec 2025 - Shareholders to vote on director elections, auditor ratification, and key share issuance proposals.VERO
Proxy Filing1 Dec 2025 - Vote sought on a reverse stock split to maintain Nasdaq listing and avoid delisting risk.VERO
Proxy Filing1 Dec 2025 - Vote sought to authorize a reverse stock split to maintain Nasdaq listing and enhance share value.VERO
Proxy Filing1 Dec 2025 - Approval sought for share issuance tied to convertible notes after major debt restructuring.VERO
Proxy Filing1 Dec 2025 - Amended registration statement for a public offering, with auditor consent and executive sign-off.VERO
Registration Filing29 Nov 2025